FDA Approves Tzield for Children Ages 1+ With Stage 2 Type 1 Diabetes
First disease-modifying therapy approved to delay disease progression in the youngest patients
The U.S. Food and Drug Administration approved an expanded indication for Tzield (teplizumab-mzwv) to delay the progression from stage 2 to stage 3 type 1 diabetes in children as young as 1 year old. This approval represents a major milestone for families at risk, as Tzield becomes the first disease-modifying therapy that targets the underlying autoimmune process of type 1 diabetes.
For the first time, children diagnosed with stage 2 type 1 diabetes can receive a 14-day infusion and gain a median of two years without needing insulin therapy. This expansion builds on the initial 2022 approval for individuals aged 8 and older, now bringing hope to younger children and their families.
Understanding Type 1 Diabetes Stages
Click on each stage to learn how Tzield intervenes in the disease process
Why early intervention matters: Type 1 diabetes can progress rapidly in young children. Early detection and intervention provide families with critical years to prepare, reducing the immediate burden of intensive insulin management during crucial childhood development.
Real-World Impact: With and Without Tzield
- Early insulin dependence required
- Daily blood sugar monitoring
- Insulin pump management
- Continuous caregiving demands
- Frequent health management interruptions
- Extended period without insulin
- More normal childhood experiences
- Reduced daily caregiving burden
- Time for family adjustment
- Developmental continuity preserved
Clinical significance: A median delay of two years represents precious developmental time—early school experiences, friendship building, physical growth, and family stability—managed without the daily complexities of insulin therapy.
Key Approval Facts
Early Screening Is Essential
Type 1 diabetes develops through distinct, identifiable stages. Early screening can detect stage 2 disease, which is the critical window for accessing Tzield therapy. This applies to families with a history of type 1 diabetes and those without.
Young children can progress rapidly through disease stages, making early detection essential for intervention. Breakthrough T1D offers screening resources and research-based detection programs including home-based testing kits. Early screening could mean the difference between years of normal childhood and immediate insulin dependence.
Get Your Child Screened Today
If your child is ages 1 and older—with or without family history of type 1 diabetes—early screening is simple, accessible, and could qualify them for Tzield therapy.
Find Screening ResourcesA Legacy of Focused Research
Decades of persistence led to this breakthrough
Four decades of commitment: This approval represents sustained research investment from basic discovery through clinical validation. It demonstrates how coordinated efforts among researchers, funding organizations, regulatory agencies, and industry partners can transform treatment possibilities for vulnerable populations.
What This Means for Clinical Practice
The expansion of Tzield to younger children provides clinicians with a new therapeutic option that addresses the underlying autoimmune process rather than managing symptoms alone. This enables a shift toward proactive immune intervention in the earliest disease stages.
For families with children diagnosed with stage 2 type 1 diabetes, this approval creates a critical window of opportunity. Early identification combined with Tzield therapy provides measurable additional time—a median of two years—without the demands of daily insulin therapy.
Global Access and Continued Development
Beyond the United States, teplizumab (under the brand name Teizeild) is approved in the European Union, United Kingdom, Canada, China, Israel, Saudi Arabia, the United Arab Emirates, and Kuwait for adults and children ages 8 and older with stage 2 type 1 diabetes. Expansion to younger children ages 1+ is underway in these markets as international partners work to expand access.
Future developments: Breakthrough T1D continues to fund next-generation disease-modifying therapies with potential to further improve type 1 diabetes outcomes. The organization is supporting early-stage companies and clinical trials to advance multiple disease-modifying options through the pipeline.
Related Health and Science Coverage
Explore our coverage of other health breakthroughs and disease research:
What This Approval Means for Families
The FDA approval of Tzield for children ages 1 and older marks a significant moment in type 1 diabetes treatment. For the first time, families with young children diagnosed with stage 2 type 1 diabetes have a disease-modifying therapy that delays progression to insulin-dependent disease.
This approval builds on decades of focused research—from laboratory discoveries to large-scale clinical trials involving hundreds of participants. It represents the value of sustained commitment to understanding autoimmune disease mechanisms and the importance of early detection.
For families at risk, early screening to identify stage 2 disease enables access to Tzield therapy—gaining a median of two additional years without daily insulin management. This represents a meaningful window of time for childhood growth, development, and family adjustment.
Information sourced from FDA official approvals, Breakthrough T1D, Sanofi, and TrialNet.
